Assess whether the primary endpoint will survive FDA scrutiny (701a22)

SITUATION A mid-size sponsor after a complete response letter cannot treat a site-change that invalidates stability claims as incidental context on phase-3 protocol with endpoint-sensitivity issues. Pharmacovigilance medical reviewer must close the primary endpoint will from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Phase-3 protocol with endpoint-sensitivity issues reads as Proceed under protocol once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population. 2. Phase-3 protocol with endpoint-sensitivity issues is closer to Pause the pathway after a site-change that invalidates stability claims; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in phase-3 protocol with endpoint-sensitivity issues for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Phase-3 protocol with endpoint-sensitivity issues is missing the fact pharmacovigilance medical reviewer needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims). If phase-3 protocol with endpoint-sensitivity issues cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.